Moderna Not Immune To COVID-19 Effects On Trials
US Lockdown Hits Rare Disease Trials
Company suspends enrolment to trials as coronavirus travel restrictions bite.
You may also be interested in...
Moderna is pursuing a single-antigen strategy even though some of its mRNA vaccines have included multiple antigens; the SARS-CoV-2 spike protein likely provides the best antigen for developing immunity against the virus.
Non-profit approach is reassuring for healthcare payers, but vaccines won’t be ready to stop pandemic at its peak.
While Moderna and others frontrunners aim for a 2020 emergency use approval, Merck believes a more deliberate approach will pay off in the long term.